Urolithiasis is a common multifactorial urological disorder that is characterized by stone formation. Interleukin (IL)-1 and IL-6 are pro-inflammatory cytokines that might be linked with urolithiasis. The single nucleotide polymorphisms within the IL-1 and IL-6 cytokine genes altered the cytokine expression levels. Our aim was to investigate the potential of IL-1β (-511 C>T), IL-6 (-174 G>C, -572 G>C, -597 G>A) and IL-1RN VNTR gene polymorphisms to be a genetic marker for urinary stone disease. The polymorphisms studied in the promoter regions of IL-1β and IL-6 genes did not reveal a strong association with urolithiasis when compared to the control group (p = 0.293, 0.871, 0.921, 0.536, respectively). However, a significant difference was observed between control and patient groups for IL-1RN VNTR gene polymorphism (χ2 = 6.131, d.f. = 2, p = 0.047). Our data provide evidence that IL-1RN VNTR gene polymorphism may be involved in the pathogenesis of urinary stone formation, contributing to genetic susceptibility for urolithiasis.

Keywords:
Urolithiasis, Interleukin-1, Interleukin-6, Single nucleotide polymorphism
1.
Muslumanoglu AY, Binbay M, Yuruk E, Akman T, Tepeler A, Esen T, Tefekli AH: Updated epidemiologic study of urolithiasis in turkey. I. Changing characteristics of urolithiasis. Urol Res 2010;39:309-314.
2.
Hess B: Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi (in German). Ther Umsch 2003;60:79-87.
3.
Koyuncu HH, Yencilek F, Eryildirim B, Sarica K: Family history in stone disease: how important is it for the onset of the disease and the incidence of recurrence? Urol Res 2010;38:105-109.
4.
Jackman SV, Kibel AS, Ovuworie CA, Moore RG, Kavoussi LR, Jarrett TW: Familial calcium stone disease: TaqI polymorphism and the vitamin d receptor. J Endourol 1999;13:313-316.
5.
Khan SR, Canales BK: Genetic basis of renal cellular dysfunction and the formation of kidney stones. Urol Res 2009;37:169-180.
6.
Vezzoli G, Tanini A, Ferrucci L, Soldati L, Bianchin C, Franceschelli F, Malentacchi C, Porfirio B, Adamo D, Terranegra A, Falchetti A, Cusi D, Bianchi G, Brandi ML: Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol 2002;13:2517-2523.
7.
Rhee E, Santiago L, Park E, Lad P, Bellman GC: Urinary IL-6 is elevated in patients with urolithiasis. J Urol 1998;160:2284-2288.
8.
Tsai FJ, Lu HF, Yeh LS, Hsu CD, Chen WC: Lack of evidence for the association of tumor necrosis factor-α gene promoter polymorphism with calcium oxalate stone and bladder cancer patients. Urol Res 2001;29:412-416.
9.
Dinarello CA: Proinflammatory cytokines. Chest 2000;118:503-508.
10.
Auron PE: The interleukin-1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev 1998;9:221-237.
11.
Castell JV, Andus T, Kunz D, Heinrich PC: Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat. Ann NY Acad Sci 1989;557:87-101.
12.
Steinkasserer A, Koelble K, Sim RB: Length variation within intron 2 of the human IL-1 receptor antagonist protein gene (IL-1RN). Nucleic Acids Res 1991;19:5095.
13.
Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-404.
14.
Vamvakopoulos JE, Taylor CJ, Morris-Stiff GJ, Green C, Metcalfe S: The interleukin-1 receptor antagonist gene: a single-copy variant of the intron 2 variable number tandem repeat (VNTR) polymorphism. Eur J Immunogenet 2002;29:337-340.
15.
Di Giovine FS, Takhsh E, Blakemore AI, Duff GW: Single base polymorphism at -511 in the human interleukin-1β. Hum Mol Genet 1992;1:450.
16.
Hurme M, Lehtimaki T, Jylha M, Karhunen PJ, Hervonen A: Interleukin-6 -174G/C polymorphism and longevity: a follow-up study. Mech Ageing Dev 2005;126:417-418.
17.
Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL: Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003;88:255-259.
18.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
19.
Pak CY, Resnick MI, Preminger GM: Ethnic and geographic diversity of stone disease. Urology 1997;50:504-507.
20.
Indridason OS, Birgisson S, Edvardsson VO, Sigvaldason H, Sigfusson N, Palsson R: Epidemiology of kidney stones in Iceland: a population-based study. Scand J Urol Nephrol 2006;40:215-220.
21.
Ljunghall S: Renal stone disease. Studies of epidemiology and calcium metabolism. Scand J Urol Nephrol 1977;41:1-96.
22.
Holmes RP, Goodman HO, Hart LJ, Assimos DG: Relationship of protein intake to urinary oxalate and glycolate excretion. Kidney Int 1993;44:366-372.
23.
Chen YY, Roseman JM, Devivo MJ, Huang CT: Geographic variation and environmental risk factors for the incidence of initial kidney stones in patients with spinal cord injury. J Urol 2000;164:21-26.
24.
Pourmand G, Nasseh H, Sarrafnejad A, Mehrsai A, Hamidi Alamdari D, Nourijelyani K, Shekarpour L: Urinary Tamm-Horsfall protein and citrate: a case-control study of inhibitors and promoters of calcium stone formation. Urol J 2005;2:79-85.
25.
Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A: Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int 2004;72 (suppl 1):6-10.
26.
Baumann JM, Affolter B, Caprez U, Clivaz C, Gluck Z, Weber R: Stabilization of calcium oxalate suspension by urinary macromolecules, probably an efficient protection from stone formation. Urol Int 2007;79:267-272.
27.
Ruggiero M, Pacini S, Amato M, Aterini S, Chiarugi V: Association between vitamin D receptor gene polymorphism and nephrolithiasis. Miner Electrolyte Metab 1999;25:185-190.
28.
Chen WC, Wu HC, Lu HF, Chen HY, Tsai FJ: Calcitonin receptor gene polymorphism: a possible genetic marker for patients with calcium oxalate stones. Eur Urol 2001;39:716-719.
29.
Mittal RD, Bid HK, Manchanda PK, Kapoor R: Association of interleukin-1β gene and receptor antagonist polymorphisms with calcium oxalate urolithiasis. J Endourol 2007;21:1565-1570.
30.
Mittal RD, Bid HK, Manchanda PK: Genotype and haplotype determination of IL- 1β (g. -511C>T and g. +3954C>T) and (IL1RN) in pediatric nephrolithiasis. Clin Chim Acta 2007;379:42-47.
31.
Chen WC, Wu HC, Chen HY, Wu MC, Hsu CD, Tsai FJ: Interleukin-1β gene and receptor antagonist gene polymorphisms in patients with calcium oxalate stones. Urol Res 2001;29:321-324.
32.
Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY: Increased excretions of β2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000;85:207-214.
33.
Hurme M, Santtila S: IL-1 receptor antagonist (IL-1Ra) plasma levels are coordinately regulated by both IL-1Ra and IL-1β genes. Eur J Immunol 1998;28:2598-2602.
34.
Hirano T: Interleukin-6 and its receptor: ten years later. Int Rev Immunol 1998;16:249-284.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.